Manufacturer with High Purity and Stable Quality
Chemical Name: Pregabalin
CAS: 148553-50-8
Pregabalin is a second-generation antiepileptic drug (AED)
API High Quality, Commercial Production
| Chemical Name |
Pregabalin |
| CAS Number |
148553-50-8 |
| CAT Number |
RF-API57 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C8H17NO2 |
| Molecular Weight |
159.23 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Off-White Powder |
| Identification |
A. Meets the Requirement
B. IR: Similar to Reference Substance |
| Loss on Drying |
≤0.50% |
| Specific Rotation |
+10.0°~+13.0° |
| Related Substances |
|
| Any Single Impurity |
≤0.10% |
| Total Impurities |
≤0.80% |
| Purity By HPLC R-Isomer |
≤0.15% |
| Residue on Ignition |
≤0.10% |
| Residual Solvents |
|
| Isopropyl Alcohol |
≤5000ppm |
| Ethyl Acetate |
≤5000ppm |
| Heavy Metals |
≤10ppm |
| Chlorides |
≤0.05% |
| Assay |
98.0%~102.0% |
| Test Standard |
Enterprise Standard |
| Usage |
Active Pharmaceutical Ingredient (API); Antiepileptic Drug API |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Pregabalin is a second- generation antiepileptic drug (AED) known with the proprietary brand name of Lyrica (Pfizer, Tadworth) in the UK and USA. Adjunctive therapy of focal seizures with and without secondary generalization. Pregabalin is a Anticonvulsant and antiepileptic drug used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its use for epilepsy is as an add-on therapy for partial seizures with or without secondary generalization in adults. Some off-label uses of pregabalin include, restless leg syndrome, migraine, social phobia, panic disorder, mania, bipolar disorder, and alcohol withdrawal. Pregabalin is a new antiepileptic drug, having a γ-amino butyric acid structure on its molecular structure, which has anticonvulsant effects, and is successfully developed by the company Pfizer for the treatment of peripheral neuropathic pain, or adjuvant treatment of partial seizures. In December 2008, the US Food and Drug Administration (FDA) approved pregabalin (trade name "Lyrica") for the treatment of diabetic peripheral neuropathic pain (DPN) and postherpetic neuralgia (PHN)which are Both the most common neuropathic pains. Neuropathic pain is one of the most difficult chronic pain syndromes to treat, dull pain, burning, tingling as the main feature, there are a lot of incentives of neuralgia, diabetes, infections (such as herpes zoster), cancer and AIDS, etc. can cause neurological pain, in Europe about 3% of the population suffer from neuralgia torture.